300653 正海生物
已收盘 09-10 15:00:00
资讯
新帖
简况
股市必读：正海生物新发布《关于召开2026年第二次临时股东会的提示性公告》
证券之星 · 02:34
股市必读：正海生物新发布《关于召开2026年第二次临时股东会的提示性公告》
股市必读：正海生物（300653）9月3日董秘有最新回复
证券之星 · 09-04
股市必读：正海生物（300653）9月3日董秘有最新回复
正海生物：公司会结合实际经营情况及长期发展战略，综合考量并购事宜
证券之星 · 08-27
正海生物：公司会结合实际经营情况及长期发展战略，综合考量并购事宜
公司问答丨正海生物：公司口腔修复膜取得印度尼西亚卫生部批准的D类注册证
格隆汇 · 08-26
公司问答丨正海生物：公司口腔修复膜取得印度尼西亚卫生部批准的D类注册证
公司问答丨正海生物：目前钙硅生物陶瓷口腔骨修复材料已经正式进院销售 产品现已在全国25个省份实现省级挂网
格隆汇 · 08-26
公司问答丨正海生物：目前钙硅生物陶瓷口腔骨修复材料已经正式进院销售 产品现已在全国25个省份实现省级挂网
正海生物：持续通过巩固产品优势、强化前瞻性技术布局、加大产品开发推广、深化降本增效等措施
证券之星 · 08-26
正海生物：持续通过巩固产品优势、强化前瞻性技术布局、加大产品开发推广、深化降本增效等措施
正海生物：公司始终立足再生医学核心主业
证券之星 · 08-26
正海生物：公司始终立足再生医学核心主业
正海生物：本次3+N集采涉及省份有13个
证券之星 · 08-26
正海生物：本次3+N集采涉及省份有13个
正海生物：膜粉协同是依托现有口腔学术与销售体系
证券之星 · 08-26
正海生物：膜粉协同是依托现有口腔学术与销售体系
正海生物（300653）2026年中报简析：净利润同比下降27.85%，公司应收账款体量较大
证券之星 · 08-26
正海生物（300653）2026年中报简析：净利润同比下降27.85%，公司应收账款体量较大
图解正海生物中报：第二季度单季净利润同比下降5.02%
证券之星 · 08-25
图解正海生物中报：第二季度单季净利润同比下降5.02%
公司问答丨正海生物：公司活性生物骨产品的推广入院工作总体有序开展 产品推广应用反馈良好
格隆汇 · 08-24
公司问答丨正海生物：公司活性生物骨产品的推广入院工作总体有序开展 产品推广应用反馈良好
正海生物：坚持“销售一代、注册一代、临床一代、研发一代”的产品阶梯式开发策略
证券之星 · 08-24
正海生物：坚持“销售一代、注册一代、临床一代、研发一代”的产品阶梯式开发策略
正海生物：扎实推进活性生物骨的市场渗透与学术推广
证券之星 · 08-24
正海生物：扎实推进活性生物骨的市场渗透与学术推广
股市必读：正海生物（300653）8月18日董秘有最新回复
证券之星 · 08-19
股市必读：正海生物（300653）8月18日董秘有最新回复
正海生物：正海投资不属于上市公司范畴
证券之星 · 08-18
正海生物：正海投资不属于上市公司范畴
正海生物：宫腔修复膜已进入注册审评阶段
证券之星 · 08-18
正海生物：宫腔修复膜已进入注册审评阶段
正海生物：做再生医学领域领导者
证券之星 · 08-18
正海生物：做再生医学领域领导者
股市必读：正海生物（300653）8月17日董秘有最新回复
证券之星 · 08-18
股市必读：正海生物（300653）8月17日董秘有最新回复
正海生物：皮肤修复膜适应症为用于真皮层缺损的创面修复
证券之星 · 08-17
正海生物：皮肤修复膜适应症为用于真皮层缺损的创面修复
公司概况
公司名称：
烟台正海生物科技股份有限公司
所属行业：
专用设备制造业
上市日期：
2017-05-16
主营业务：
烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑（脊）膜补片、活性生物骨、钙硅生物陶瓷口腔骨修复材料、皮肤修复膜。公司是国家首批专精特新“小巨人”企业、国家知识产权示范企业、国家智能制造优秀场景企业、高新技术企业。
发行价格：
11.72
{"stockData":{"symbol":"300653","market":"SZ","secType":"STK","nameCN":"正海生物","latestPrice":15.15,"timestamp":1789023798000,"preClose":15.61,"halted":0,"volume":1832200,"delay":0,"changeRate":-0.0295,"floatShares":180000000,"shares":180000000,"eps":0.3847,"marketStatus":"已收盘","change":-0.46,"latestTime":"09-10 15:00:00","open":15.6,"high":15.6,"low":15.12,"amount":27909000,"amplitude":0.0307,"askPrice":15.16,"askSize":12,"bidPrice":15.15,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.3847,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"adjPreClose":15.61,"symbolType":"stock","openAndCloseTimeList":[[1789003800000,1789011000000],[1789016400000,1789023600000]],"highLimit":17.17,"lowLimit":14.05,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180000000,"isCdr":false,"pbRate":3.22,"roa":"--","peRate":39.381336,"roe":"3.71%","epsLYR":0.46,"committee":0.23764,"marketValue":2727000000,"turnoverRate":0.0102,"status":1,"floatMarketCap":2727000000},"requestUrl":"/m/hq/s/300653/wiki","defaultTab":"wiki","newsList":[{"id":"2666518887","title":"股市必读：正海生物新发布《关于召开2026年第二次临时股东会的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666518887?lang=zh_cn&edition=full","pubTime":"2026-09-11 02:34","pubTimestamp":1789065251,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，正海生物报收于15.15元，下跌2.95%，换手率1.02%，成交量1.83万手，成交额2790.9万元。当日关注点交易信息汇总：9月10日主力资金净流出247.52万元，占总成交额8.87%。公司公告汇总：正海生物将于9月15日召开2026年第二次临时股东大会，审议修订《董事会议事规则》议案，股权登记日为9月8日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664603806","title":"股市必读：正海生物（300653）9月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664603806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664603806?lang=zh_cn&edition=full","pubTime":"2026-09-04 02:05","pubTimestamp":1788458716,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，正海生物报收于15.08元，下跌1.11%，换手率1.01%，成交量1.81万手，成交额2730.03万元。董秘最新回复投资者： 公司在研发周期转产周期销售推广周期方面是否可以提效提速？当日关注点交易信息汇总：9月3日主力资金净流入163.97万元，占总成交额6.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662670080","title":"正海生物：公司会结合实际经营情况及长期发展战略，综合考量并购事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2662670080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662670080?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:48","pubTimestamp":1787834889,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物(300653)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有无回购或并购计划？理财产品利率下降的时点是否有计划充分合理的利用手中现金？改善公司经营现状？正海生物回复：尊敬的投资者您好，公司会结合实际经营情况及长期发展战略，综合考量并购事宜。若有相关回购或并购进展，公司将依法履行相关审议程序并及时进行信息披露。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300653","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662945727","title":"公司问答丨正海生物：公司口腔修复膜取得印度尼西亚卫生部批准的D类注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2662945727","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662945727?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:37","pubTimestamp":1787737033,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","BK0251","300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794392","title":"公司问答丨正海生物：目前钙硅生物陶瓷口腔骨修复材料已经正式进院销售 产品现已在全国25个省份实现省级挂网","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794392","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662794392?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:35","pubTimestamp":1787736921,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795092","title":"正海生物：持续通过巩固产品优势、强化前瞻性技术布局、加大产品开发推广、深化降本增效等措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795092?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:12","pubTimestamp":1787731941,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物08月26日在投资者关系平台上答复投资者关心的问题。另外希望公司坚持开拓海外市场加创新口腔产品渡过内卷周期，熬死其他企业巩固市场份额！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600034548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795024","title":"正海生物：公司始终立足再生医学核心主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795024?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:12","pubTimestamp":1787731939,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物08月26日在投资者关系平台上答复投资者关心的问题。专利转化也不是有什么就买什么，是否有的放矢会更好正海生物回复：尊敬的投资者您好，公司始终立足再生医学核心主业，依托自身生物再生材料技术平台开展产品布局与技术转化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600034545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0251","300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795049","title":"正海生物：本次3+N集采涉及省份有13个","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795049?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:12","pubTimestamp":1787731935,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物08月26日在投资者关系平台上答复投资者关心的问题。迈普医学算上脑膜胶达到接近一亿销售额，公司对此有何感想？正海生物回复：尊敬的投资者您好，本次3+N集采涉及省份有13个，中标价格随集采规则同步调整，实际采购执行情况，要结合各省执行集采落地、医疗机构自主选择等多重因素来看。公司将全力保障集采区域产品供应链稳定、持续做好终端临床配套服务，最大化落实集采放量优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600034539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795094","title":"正海生物：膜粉协同是依托现有口腔学术与销售体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795094?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:12","pubTimestamp":1787731933,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物08月26日在投资者关系平台上答复投资者关心的问题。膜粉协同是依托现有口腔学术与销售体系，为临床提供膜骨组合修复整体解决方案，目前钙硅生物陶瓷口腔骨修复材料已经正式进院销售，产品现已在全国25个省份实现省级挂网，新品放量需要一定的周期，公司将持续强化学术推广，拓展终端临床覆盖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600034536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750728","title":"正海生物（300653）2026年中报简析：净利润同比下降27.85%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750728","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750728?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:43","pubTimestamp":1787697821,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期正海生物发布2026年中报。截至本报告期末，公司营业总收入1.6亿元，同比下降14.94%，归母净利润3330.61万元，同比下降27.85%。本报告期正海生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达72.03%。筹资活动产生的现金流量净额变动幅度为39.13%,原因:分配股利减少。去年的净利率为22.63%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于正海生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600011721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662208053","title":"图解正海生物中报：第二季度单季净利润同比下降5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662208053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662208053?lang=zh_cn&edition=full","pubTime":"2026-08-25 01:38","pubTimestamp":1787593091,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物2026年中报显示，上半年度公司主营收入1.6亿元，同比下降14.94%；归母净利润3330.61万元，同比下降27.85%；扣非净利润2715.7万元，同比下降31.74%；其中2026年第二季度，公司单季度主营收入7874.35万元，同比下降12.92%；单季度归母净利润1855.68万元，同比下降5.02%；单季度扣非净利润1514.9万元，同比下降5.02%；负债率9.97%，投资收益113.97万元，财务费用-9.12万元，毛利率82.37%。财报数据概要请见下图:本文数据来源于正海生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500004611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222798","title":"公司问答丨正海生物：公司活性生物骨产品的推广入院工作总体有序开展 产品推广应用反馈良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222798","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661222798?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:38","pubTimestamp":1787564316,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","BK0251","300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661357224","title":"正海生物：坚持“销售一代、注册一代、临床一代、研发一代”的产品阶梯式开发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2661357224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661357224?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:42","pubTimestamp":1787560926,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物(300653)08月24日在投资者关系平台上答复投资者关心的问题。投资者提问：上个月给公司建议的冠昊生物三代双层脑膜今日已完成临床 开始投产及商业化！请问公司老产品的迭代创新方面有何感想和规划？正海生物回复：尊敬的投资者您好，公司高度重视技术创新工作，持续关注产业领域发展趋势和临床需求，坚持“销售一代、注册一代、临床一代、研发一代”的产品阶梯式开发策略，不断优化现有产品性能，做好技术储备，追求产品和技术的可持续竞争优势。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400022155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222113","title":"正海生物：扎实推进活性生物骨的市场渗透与学术推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661222113?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:27","pubTimestamp":1787560034,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物08月24日在投资者关系平台上答复投资者关心的问题。投资者提问：九源基因半年报业绩中骨优导销售额逾5亿，且多能活性骨已拿证在即，即将开始商业化，注射型骨优导已研发数年！骨修复材料领域临床需求多样、技术路径并存。公司坚持自主研发与临床价值导向，扎实推进活性生物骨的市场渗透与学术推广，持续提升自身产品力与患者临床获益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0251","300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660943594","title":"股市必读：正海生物（300653）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660943594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660943594?lang=zh_cn&edition=full","pubTime":"2026-08-19 03:25","pubTimestamp":1787081113,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，正海生物报收于15.05元，下跌0.92%，换手率0.95%，成交量1.72万手，成交额2580.5万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900003469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660146749","title":"正海生物：正海投资不属于上市公司范畴","url":"https://stock-news.laohu8.com/highlight/detail?id=2660146749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660146749?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:51","pubTimestamp":1787057515,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物08月18日在投资者关系平台上答复投资者关心的问题。是否具有为正海生物寻找并购标的的职责？若有相关进展，公司将依法履行相关审议程序并及时进行信息披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800039915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660459239","title":"正海生物：宫腔修复膜已进入注册审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2660459239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660459239?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:36","pubTimestamp":1787024183,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物08月18日在投资者关系平台上答复投资者关心的问题。能否在搭载宫腔修复膜使用的同时研发出注射款？公司将根据项目进展及信息披露规则履行信息披露义务，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800016246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0251","300653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660459444","title":"正海生物：做再生医学领域领导者","url":"https://stock-news.laohu8.com/highlight/detail?id=2660459444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660459444?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:33","pubTimestamp":1787023988,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物(300653)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司未来产品方向是侧重医美类产品？还是老龄化相关术式刚需耗材？正海生物回复：尊敬的投资者您好，公司立足于再生医学，坚持“做再生医学领域领导者”的企业愿景，在产品布局方面，积极研究和发展包括支架材料、信号分子、种子细胞在内的产品和技术，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800016040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431117","title":"股市必读：正海生物（300653）8月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431117?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:55","pubTimestamp":1786989313,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，正海生物报收于15.19元，下跌1.11%，换手率1.39%，成交量2.5万手，成交额3779.33万元。董秘最新回复投资者： 威高瑞邦已具备注射型rhbmp活性骨，对此公司有何感想？目前公司皮肤修复膜适应症为用于真皮层缺损的创面修复。当日关注点交易信息汇总：8月17日主力资金净流出177.42万元，占总成交额4.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800002024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0046","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106677","title":"正海生物：皮肤修复膜适应症为用于真皮层缺损的创面修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106677","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660106677?lang=zh_cn&edition=full","pubTime":"2026-08-17 09:15","pubTimestamp":1786929312,"startTime":"0","endTime":"0","summary":"证券之星消息，正海生物(300653)08月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司在医美协会上的关于脱细胞注射的发言是否代表公司的皮肤修复膜可以通过注射起到填充的作用正海生物回复：尊敬的投资者您好，ECM材料在医美相关领域的应用潜力受到市场较多关注，相关讨论逐渐增多。目前公司皮肤修复膜适应症为用于真皮层缺损的创面修复。感谢您的关注与支持！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700002617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300653","BK0251","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789084656432,"stockEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.004},{"period":"3month","weight":0.0236},{"period":"6month","weight":-0.2413},{"period":"1year","weight":-0.2487},{"period":"ytd","weight":-0.2284}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0241},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.032},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台正海生物科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"14294人(较上一季度减少8.77%)","perCapita":"12592股","listingDate":"2017-05-16","address":"山东省烟台市福山区经济技术开发区南京大街7号","registeredCapital":"18000万元","survey":" 烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口腔修复膜、可吸收硬脑（脊）膜补片、活性生物骨、钙硅生物陶瓷口腔骨修复材料、皮肤修复膜。公司是国家首批专精特新“小巨人”企业、国家知识产权示范企业、国家智能制造优秀场景企业、高新技术企业。","listedPrice":11.72},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"正海生物,300653,正海生物股票,正海生物股票老虎,正海生物股票老虎国际,正海生物行情,正海生物股票行情,正海生物股价,正海生物股市,正海生物股票价格,正海生物股票交易,正海生物股票购买,正海生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"正海生物(300653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供正海生物(300653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}